Last reviewed · How we verify
intraocular injections of bevacizumab — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
intraocular injections of bevacizumab (intraocular injections of bevacizumab) — Samsung Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| intraocular injections of bevacizumab TARGET | intraocular injections of bevacizumab | Samsung Medical Center | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- intraocular injections of bevacizumab CI watch — RSS
- intraocular injections of bevacizumab CI watch — Atom
- intraocular injections of bevacizumab CI watch — JSON
- intraocular injections of bevacizumab alone — RSS
Cite this brief
Drug Landscape (2026). intraocular injections of bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/intraocular-injections-of-bevacizumab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab